Bejar DE, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients:currentperspectives. Health Med Ther. 2014;5:115–25.

Google Scholar 

Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003;48(1):39–57.

Article  PubMed  Google Scholar 

Terezakis SA, Wharam MD. Radiotherapy for rhabdomyosarcoma:indications and outcome. Clin Oncol R CollRadiol. 2013;25:27–35.

Article  CAS  Google Scholar 

Viswanathan S, George S, Ramadwar M, et al. Extraconal orbital tumors in children—a spectrum. Virchows Arch. 2009;454:703–13.

Article  PubMed  Google Scholar 

Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993;259:1450–3.

Article  CAS  PubMed  Google Scholar 

Sohaib SA, Moseley I, Wright JE. Orbital rhabdomyosarcoma-the radiological characteristics. Clin Radiol. 1998;53:357–62.

Article  CAS  PubMed  Google Scholar 

Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-IA final report. Cancer. 1988;61:209–20.

Article  CAS  PubMed  Google Scholar 

Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912–34.

Article  CAS  PubMed  Google Scholar 

Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57.

Article  CAS  PubMed  Google Scholar 

Zhenfang Du, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.

Article  Google Scholar 

Krug M, Hilgeroth A. Recent advances in the development of multi- kinase inhibitors. Mini Rev Med Chem. 2008;8(13):1312–27.

Article  CAS  PubMed  Google Scholar 

Broekman F, Giovannetti E, Peters G. Tyrosine kinase inhibitors: multi- targeted or single-targeted? World J Clin Oncol. 2011;2(2):80–93.

Article  PubMed  PubMed Central  Google Scholar 

Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non- small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488–95.

Article  CAS  PubMed  Google Scholar 

Janne PA, Neal JW, Camidge DR, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. J Clin Oncol. 2019;37(15_suppl):9007.

Article  Google Scholar 

Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38(15_suppl):9514.

Article  Google Scholar 

Chia P, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. ClinEpidemiol. 2014;6:423–32.

Google Scholar 

Shaw A, Ou S, Bang Y, et al. Crizotinib in ROS1-rearranged non-small- cell lung cancer. N Engl J Med. 2014;371(21):1963–71.

Article  PubMed  PubMed Central  Google Scholar 

Stirrups R. Neratinib and capecitabine for breast cancer brain metasta- ses. Lancet Oncol. 2019;20(4): e197.

Article  PubMed  Google Scholar 

Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncol. 2020;16(7):247–54.

Article  CAS  PubMed  Google Scholar 

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocel- lular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.

Article  CAS  PubMed  Google Scholar 

Abou-Alfa G, Meyer T, Cheng A, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Qin S, Gu S, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: a randomized, placebo-controlled, double-blind, phase III study. J Clin Oncol. 2020;38(15):4507.

Article  Google Scholar 

Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a ran- domised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.

Article  CAS  PubMed  Google Scholar 

Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–75.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Hu X, Jiang J, et al. A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist. 2020;25(5):e833–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poddubskaya E, Baranova M, Allina D, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocar- cinoma. Exp Hematol Oncol. 2018;7:21.

Article  PubMed  PubMed Central  Google Scholar 

Gainor JFCG, Kim D-W, et al. Registrational dataset from the phase I/ II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15_suppl):9515.

Article  Google Scholar 

Subbiah V, Hu MIN, Gainor JF, et al. Clinical activity of the RET inhibi- tor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol. 2020;38(15_suppl):109.

Article  Google Scholar 

Drilon A, Clark J, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previ- ously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018;8(7):812.

Article  CAS  PubMed  PubMed Central  Google Scholar 

AbbaspourBabaei M, Kamalidehghan B, Saleem M, et al. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des DevelTher. 2016;10:2443–59.

Google Scholar 

Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melano- mas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J ClinOncol. 2013;31(26):3182–90.

Article  CAS  Google Scholar 

Mei L, Du W, Idowu M, et al. Advances and challenges on management of gastrointestinal stromal tumors. Front Oncol. 2018;8:135.

Article  PubMed  PubMed Central  Google Scholar 

Lawrence WJ, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma study group. Cancer. 1997;80(6):1165–70.

Article  PubMed  Google Scholar 

Hou J, Dong J, Sun L, et al. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med. 2011;9:64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim L, Wu CC, Hsu YT, et al. Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer. Taiwan J Obstet Gynecol. 2019;2019(58):105e110.

Google Scholar 

Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA- 665752. Proc Natl Acad Sci USA. 2006;103:2316–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081–8.

Article  CAS  PubMed  Google Scholar 

Anastasi S, Giordano S, Sthandier O, et al. A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive met kinase activation on myogenic differentiation. J Cell Biol. 1997;137(5):1057–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camassei FD, McDowell HP, Deloris MA, et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res. 2008;14(13):4119–27.

Article  Google Scholar 

Paccez JD, Vogelsang M, Parker MI, et al. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer. 2014;134:1024–33.